Swiss medtech startup CUTISS raises €18.72 million in Series B funding to help patients who suffer from large and deep skin defects
CUTISS, an innovative Swiss life science startup aiming to provide patients that suffer from large and deep skin defects with an automatically produced, personalized skin tissue therapy, denovoSkin™, today announced it has successfully closed its series B financing round.
The €18.72 million Series B funding round was oversubscribed and the fresh capital will allow CUTISS to further progress denovoSkin™, the startup’s unique personalized skin technology to treat skin defects, i.e.
The CUTISS team plans to file for market authorization with denovoSkin™ in Switzerland and in the European Union in 2022.
Its lead product candidate, denovoSkin™, has been tested in a phase I clinical trial on pediatric patients at the University Children’s Hospital in Zurich.
Dr. Daniela Marino, CEO and Co-Founder of CUTISS, commented: “We feel very lucky and privileged that we have closed an oversubscribed series B financing round.
Disclaimer: This story is auto-aggregated & summarized by a computer program and has not been created by StartupAround.
82% of successful business owners admit they have the right qualifications and backed up experience to run a company, even with limited cash flow.
Search Startup Around
Boost Your Discovery with Us
Advertise with us to boost your article, content pience, product, event, conference discovery to our readers which includes founders, startup enablers, investors and every key stakeholders from global startup eco-system.